SUNRISE CONSULTING GROUP INCORPORATED (OTC: SNRS)
"Up 100.00% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/SNRS.php

Sunrise’s mission is to become a premier investment banking and financial group for companies in Asia and the Pacific Rim, bringing value to small and medium sized companies and assisting them in becoming listed on the USA Exchanges. The company's primary target areas include China, Hong Kong, Laos, Vietnam, Malaysia, Australia and possibly others in the Pacific Rim & Southeast Asia, with mainland China being the initial major focal point. Recent growth in these countries has been in the high double digits, and Sunrise intends to capitalize on this trend by building upon and adding to its current holdings, increasing sales revenues through upcoming acquisitions, including the Cao Tian Iron Ore Mines in Hunan Province, and continually expanding its portfolio into related areas. For more information, email This email address is being protected from spam bots, you need Javascript enabled to view it or call 949-258-4411.

SNRS News:

July 2 - Sunrise Consulting Group Inc. Nears Completion of Purchase of Chinese Iron Mines

Sunrise Consulting Group Inc. (OTC: SNRS) announced that they have completed their due diligence and are making final preparations to acquire the Cao Tin Iron Ore Mines in Hunan Province, China. The process had been delayed for several months due to heavy snow storms in February, which resulted in many landslides caused by the melting of snow in the mountainous areas.

Sunrise CEO Raymond Chin commented, “We are very excited to have now completed this final phase of fact-finding and anticipate final completion of the agreement to occur very soon. Worldwide prices of iron ore have increased more than 100% since December 2007, and we are well-positioned to capitalize on this situation. We look forward to a long lasting profitable return from these mines and see a bright future ahead of us at Sunrise.”

GENTA INCORPORATED (OTCBB: GNTA)
"Up 54.76% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/GNTA.php

Genta Incorporated operates as a biopharmaceutical company with a diversified product portfolio that is focused on delivering products for the treatment of patients with cancer. Its research portfolio consists of two programs, DNA/RNA Medicines and Small Molecules. The company's lead compound from its DNA/RNA Medicines program is Genasense oblimersen sodium) injection that is designed to block the production of a protein, known as Bcl-2, which is a fundamental cause of the inherent resistance of cancer cells to anticancer treatments, such as chemotherapy, radiation, and monoclonal antibodies. Genta Incorporated is recruiting patients to the AGENDA Trial, a global Phase III trial of Genasense in patients with advanced melanoma. Its lead drug in its Small Molecule program is Ganite gallium nitrate injection), which is marketed in the United States for the treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The company also develops G4544, an oral formulation of the active ingredient in Ganite, which entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. In addition, it is developing tesetaxel, an orally absorbed, semi-synthetic taxane that is in the same drug class as paclitaxel and docetaxel. The company was founded in 1988 and is based in Berkeley Heights, New Jersey.

GNTA News:

June 24 - Genta Updates Progress of its Phase 3 Trial of Genasense® in Patients with Advanced Melanoma

Clinical Study on Track to Complete Accrual in Fourth Quarter 2008

Genta Incorporated (OTCBB: GNTA) announced the presentation of a progress update from an ongoing Phase 3 trial of Genasense® (oblimersen sodium) Injection, the Company's lead oncology product, in patients with advanced melanoma. The data were presented at a satellite investigator's meeting held in conjunction with the Adjuvant Melanoma Congress sponsored by the European Association of Dermato-Oncology (EADO) in Marseille, France on June 21, 2008.

AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from Genta's prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients identified by a biomarker who have not previously received chemotherapy. The co-primary endpoints of AGENDA are progression-free survival and overall survival. The trial is being led by the EADO in Europe and by the M.D. Anderson Cancer Center, Houston, TX in the U.S.

To date, more than one-third of the expected total number of patients have now been randomized onto the AGENDA trial. A total of 83 sites in 12 countries have been opened in Europe, the U.S., Canada, and Australia. Clinical characteristics of the first 70 patients accrued to AGENDA (not identified by treatment group) were shown to be similar to the biomarker-defined population accrued in the previous Phase 3 trial of Genasense, known as GM301. The incidence of serious adverse events in AGENDA has been somewhat lower, which probably reflects the routine use of prescribed supportive care for all patients, as well as the double-blind design of AGENDA compared with the open-label design of GM301. Target accrual of 300 patients is expected to complete in the fourth quarter of 2008, with initial data expected shortly thereafter.

ABOUT AGENDA

AGENDA is a global Phase 3, randomized, double-blind trial in patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from an antecedent randomized trial of Genasense combined with dacarbazine (DTIC) in patients who have not previously received chemotherapy (GM301). AGENDA employs a biomarker to define those patients who derived maximum clinical benefit during the preceding study. These patients are characterized by low-normal levels of LDH (lactate dehydrogenase), a tumor-derived enzyme that is readily detected in blood.

A scientific article that describes efficacy and safety results from GM301 can be accessed at www.jco.org/cgi/content/abstract/JCO.2006.06.0483v1.

ABOUT THE EADO

The EADO is an independent non-profit organization dedicated to the promotion, coordination, and improvement of clinical and laboratory research activities in the field of skin cancer. The organization has an European and international membership of dermatologists, oncologists and clinical as well as basic research scientists interested in the field of dermato-oncology. EADO provides leadership by formulating and disseminating quality standards and guide-lines for diagnosis and treatment of skin cancer, and it provides direction, coordination and organizations of clinical, therapeutic, and experimental trials.

ABOUT GENASENSE

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

UNIVERSAL ENERGY CORPORATION (OTCBB: UVSE)
"Up 32.67% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/UVSE.php

Universal Energy Corp., an independent energy company, engages in the acquisition and development of crude oil and natural gas leases in the United States and Canada. As of December 31, 2007, it had working interest in approximately 7,095 acres of land in Louisiana and Texas, as well as in Alberta, Canada. The company, formerly Universal Tanning Ventures, Inc., was founded in 2002 and is based in Lake Mary, Florida.

UVSE News:

July 1 - Universal Energy Corp. Begins Installation of Intermediate Casing at its Lone Oak Prospect in Galveston Bay, Texas

Universal Energy Corp. (OTCBB: UVSE), announced that drilling at its Lone Oak Prospect in Galveston Bay, Texas has reached a measured depth of 11,586 feet. Logging of the hole was completed yesterday and installation of 7 5/8 inch intermediate casing will now be installed to a depth of 11,470 feet. It is estimated that drilling operations at Lone Oak will be completed by July 12, 2008.

Billy Raley, Chief Executive Officer of Universal Energy Corp. stated "We are very excited with the progress at Lone Oak so far. It is important for oil and gas exploration and production companies throughout the United States to continue exploration within our borders." Raley continued, "Building reserves for U.S. consumers, and U.S. stockholders, should be the rallying cry for every E&P company operating within the United States."

Universal Energy Corp. is a publicly-traded energy company engaged in the acquisition and development of crude oil and natural gas leases in the United States. We pursue oil and gas prospects in partnership with oil and gas companies with exploration, development and production expertise. Our prospect areas consist of lands in Louisiana and Texas. Visit www.universalenergycorp.info for more details.

AMERICA WEST RESOURCES INCORPORATED (OTCBB: AWSR)
"Up 48.15% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/AWSR.php

Headquartered in Salt Lake City, Utah, America West Resources, Inc. is an established domestic coal producer focused on the mining of clean and compliant (low-sulfur) coal and its sale primarily to U.S. utility companies for use in generating electricity. Since 2003, the Company has extracted over 1.3 million tons of coal from its owned and operated Horizon Coal Mine based in Central Utah. For more information, visit www.AmericaCoal.com.

AWSR News:

July 2 - America West Resources Wins $8.3 Million Coal Supply Agreement With Major Power Agency in Western U.S.

Customer's Option to Purchase Excess Production Provides for Additional $12.45 Million in Potential Revenue to America West

America West Resources, Inc. (OTCBB: AWSR), a domestic coal producer with mining operations in Central Utah, announced that the Company has agreed to supply a major power agency in the Western U.S. with coal produced from its Horizon Mine pursuant to a 12-month Coal Supply Agreement with a minimum contracted value of $8.3 million. America West will also offer this agency excess production above minimum contracted tonnage, and it has agreed to use its best efforts to accept it, thereby providing America West with the opportunity to realize up to $12.45 million in additional revenue.

America West recently announced that it commenced mining operations in a second section of its Horizon Mine, which is helping the Company to further accelerate coal production. According to Alexander Walker III, President and CEO of America West, "We are delighted to become a preferred supplier of coal to this major power agency and look forward to optimizing this new relationship to strengthen our operating platform and advance America West through what is proving to be a very exciting growth period in our history."

HEARTLAND OIL & GAS CORPORATION (OTCBB: HTOG)
"Up 15.27% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/HTOG.php

Heartland Oil and Gas Corp. engages in exploration, development, production, and sale of coal bed methane in the Cherokee basin and Forest City basin of northeast Kansas. The company owns and operates oil and gas leases located on approximately 645,000 acres of property in the Forest City and Cherokee basins in eastern Kansas; 700 acres of property in Palo Pinto County, Texas; and 3,000 acres in Jack County, Texas. It also holds properties in Kansas in the south block, located on the Cherokee basin; and the north block, located in the Forest City basin. In addition, the company engages in the processing and sale of gas through pipelines from its Lancaster wells. As of December 31, 2007, Heartland Oil and Gas had proved developed net reserves of 2,410,484 thousand cubic feet of gas; and 3,002 thousand barrels of crude oil. The company was founded in 1998 and is based in Houston, Texas. Heartland Oil & Gas Corp. operates as a subsidiary of Universal Property Development and Acquisition Corporation.

HTOG News:

July 2 - Heartland Completes and Successfully Pressure Tests 4 Mile Pipeline, Installation of Flow Lines to Commence for Connection of 12 Wells Expected to Double Coalbed Methane Production

Heartland Oil and Gas Corp. (OTCBB: HTOG) (FWB: HOCA) has successfully conducted pressure testing on its new 4 mile pipeline in Kansas, signaling the completion of that pipeline. Work was then immediately commenced to install the flow lines to each of the 12 new wells to be connected in order to begin the sale of the coalbed methane being generated by those wells.

With this successful testing and anticipated connection of 12 wells, Heartland expects to double the coalbed methane production from this field in Southeast Kansas. In addition, vast additional acreage will be open for further development and drilling along the 4 miles to be accessed by the pipeline.

“We put the necessary pressure into the pipeline and found no leaks along its entire length,” reports Augie Soto, COO of Aztec Well Services, Heartland’s prime contractor on the work. “The four road crossings and 2 creek crossings were our greatest concern and they held without any problems. The 8 inch main is tied into the 12 inch main and the pipeline is secure all the way to the sales meter. We will begin installation of the 4 inch flow lines without delay and have scheduled the contractor to fracture the wells so they are ready for production as soon as we can connect them.”

MAXYGEN INCORPORATED (NASDAQ: MAXY)
"Up 27.64% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/MAXY.php

Maxygen, Inc., a biotechnology company, engages in the discovery, development, and commercialization of protein pharmaceuticals for treatment of disease and serious medical conditions in the United States. The company's product candidates comprises MAXY-G34, a granulocyte colony stimulating factor that is in Phase IIa clinical trial for the treatment of neutropenia; MAXY-VII, a factor VIIa product that is in pre-clinical stage for the treatment of hemophilia and acute bleeding conditions; and MAXY-4, a CTLA-4-Ig product for the treatment of rheumatoid arthritis and other immune or autoimmune diseases. It has a strategic alliance with Roche Holdings, Ltd. for the development and commercialization of Maxygen's portfolio of next-generation interferon alpha and beta variants for a range of indications. The company was founded in 1996 and is headquartered in Redwood City, California.

MAXY News:

July 1 - Bayer HealthCare and Maxygen Announce Hematology Agreement

*Portfolio of hemophilia drug candidates includes novel recombinant Factor VIIa
*$120 million transaction includes license to Maxygen's novel biotechnology research platform
*Phase 1 clinical testing expected to commence in third quarter

Bayer HealthCare is expanding its commitment to hemophilia with the acquisition of Maxygen’s (NASDAQ: MAXY) hemophilia program assets, including a next-generation recombinant Factor VIIa protein known as MAXY-VII. The lead therapeutic candidate is expected to enter Phase 1 clinical testing in the third quarter of 2008. The total transaction is valued at $90 million upfront with a final, potential milestone payment of $30 million. This agreement includes a license to use Maxygen’s MolecularBreeding™ technology, a novel research platform, for exploiting gene targets.

Hemophilia is an inherited bleeding disorder caused by deficient or defective blood coagulation proteins. Roughly 20 to 30 percent of patients with hemophilia develop antibodies – or inhibitors – to current therapies. In these instances a Factor VIIa is used to bypass inhibitors and help these individuals to form clots. MAXY-VII is a next generation Factor VIIa clotting factor that may offer an improved dosing regimen and safety profile. The addition of a development candidate for patients with clotting factor inhibitors could further build Bayer’s leadership position in hemophilia care where it offers the recombinant Factor VIII product, Kogenate® (antihemophilic factor [recombinant]). The company has a strong development program dedicated to hemophilia including ongoing clinical investigations into long-acting forms of Kogenate.

“MAXY-VII has the potential to be an important expansion of therapeutic options for people living with hemophilia and we are pleased to add this to our global development portfolio. The agreement fits into our growth strategy for our specialty pharmaceutical business and builds on our expertise in the commercialization and manufacturing of protein therapeutics,” said Dr. Gunnar Riemann, member of the Executive Committee of Bayer HealthCare. “Our scientists are actively collaborating with researchers in academia and biotechnology firms to leverage novel research platforms. Access to Maxygen’s MolecularBreeding™ technology provides us with another tool to expand our product pipeline.”

“This agreement allows Maxygen to capture significant value from this preclinical asset, and puts MAXY-VII in the hands of the hemophilia leader,” said Russell Howard, chief executive officer of Maxygen. “MAXY-VII has the potential to become the world’s first approved shuffled protein therapeutic, a milestone that is likely to open up many more opportunities for Maxygen’s technology. Bayer is the ideal company to move the MAXY-VII program toward that goal.”

Bayer also receives a non-exclusive license to use Maxygen’s MolecularBreeding™ technology for a broad set of genes for its internal use in its specialty pharmaceutical business. In addition, Bayer receives exclusive rights to use the technology for 30 specified gene targets in areas of strategic business interest. This novel platform allows scientists to exploit gene variation that can result in unique drug targets or novel therapeutic protein candidates.

ABOUT MAXY-VII AND HEMOPHILIA

MAXY-VII is designed to be an improved Factor VIIa for the treatment of hemophilia patients. Hemophilia is an inherited bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints or internal organs. The disease is caused by deficient or defective blood coagulation proteins, known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX. According to the World Federation of Hemophilia, about 1 in 10,000 people is born with hemophilia A and 1 in 50,000 people is born with hemophilia B. Over time, roughly 20 to 30 percent of patients develop antibodies to these replacement factors (frequently referred to as inhibitors).

ABOUT THE MOLECULARBREEDING™ DIRECTED EVOLUTION PLATFORM

MolecularBreeding™, also known as gene shuffling, is an iterative process of recombination and selection. The products of these recombined genes (proteins) are then screened for the targeted drug properties. This novel platform allows scientists to exploit gene variation that can result in unique drug targets or novel therapeutic protein candidates.

ABOUT KOGENATE® FS/KOGENATE® BAYER

Kogenate® FS (Antihemophilic Factor [Recombinant]) / KOGENATE® Bayer (Recombinant Coagulation Factor VIII [octocog alfa]) is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The safety, efficacy and overall reliability of the Kogenate® line of products are based on 20 years of clinical experience. Clinical data shows that Kogenate® provided excellent hemostatic control, was well tolerated, and has a proven safety profile in patients with hemophilia A. Kogenate® is manufactured at Bayer’s state-of-the-art biotechnology facility in Berkeley, California. The most frequently reported adverse events were local injection site reactions, dizziness and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate®. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate®.

ABOUT BAYER HEALTHCARE

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.

Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. Find more information at www.bayerscheringpharma.de.